Details for New Drug Application (NDA): 206961

NDA 206961 describes ISOPROTERENOL HYDROCHLORIDE, which is a drug marketed by 3M, Alpharma Us Pharms, Abraxis Pharm, Am Regent, Amneal, Amphastar Pharms Inc, Amring Pharms, Avet Lifesciences, Baxter Hlthcare, Cipla, Eugia Pharma, Gland Pharma Ltd, Hikma, Hospira, Intl Medication, Micro Labs, Nexus, Norvium Bioscience, Penn Life, Somerset Theraps Llc, Zydus Pharms, Armour Pharm, DEY, and Parke Davis, and is included in twenty-eight NDAs. It is available from twelve suppliers. Additional details are available on the ISOPROTERENOL HYDROCHLORIDE profile page.

The generic ingredient in ISOPROTERENOL HYDROCHLORIDE is isoproterenol hydrochloride. There are seventeen drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the isoproterenol hydrochloride profile page.

Summary for 206961

Tradename:	ISOPROTERENOL HYDROCHLORIDE
Applicant:	Nexus
Ingredient:	isoproterenol hydrochloride
Patents:	0

Pharmacology for NDA: 206961

Mechanism of Action

Adrenergic beta-Agonists

Suppliers and Packaging for NDA: 206961

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
ISOPROTERENOL HYDROCHLORIDE	isoproterenol hydrochloride	INJECTABLE;INJECTION	206961	ANDA	Nexus Pharmaceuticals Inc	14789-011	14789-011-01	10 VIAL, SINGLE-DOSE in 1 CARTON (14789-011-01) / 1 mL in 1 VIAL, SINGLE-DOSE
ISOPROTERENOL HYDROCHLORIDE	isoproterenol hydrochloride	INJECTABLE;INJECTION	206961	ANDA	Nexus Pharmaceuticals Inc	14789-015	14789-015-05	10 VIAL, SINGLE-DOSE in 1 CARTON (14789-015-05) / 5 mL in 1 VIAL, SINGLE-DOSE

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	INJECTABLE;INJECTION			Strength	0.2MG/ML
Approval Date:	Aug 2, 2017	TE:	AP	RLD:	No

Complete Access Available with Subscription